NASDAQ:XFOR

X4 Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy XFOR

*Your capital is at risk

$3.97

-0.0700 (-1.73%)

At Close: Jun 03, 2026

X4 Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 95.45. In total, the insiders bought 31.82M and sold 1.12M XFOR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	95.45
● Buy	31.82M shares
● Sell	1.12M shares
81% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence May 12, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 95.45. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 12, 2026 Sell	Common Stock S-Sale	Kirske David Chief Financial Officer	C-Suite Officer	16 961 Value: $72.8K
Jan 01, 2026 Buy	Stock Option (right to buy) A-Award	Bridger Gary Director	Director	110 000 Value: $440.0K
Jan 01, 2026 Buy	Stock Option (right to buy) A-Award	Stewart Murray Director	Director	110 000 Value: $440.0K
Jan 01, 2026 Buy	Stock Option (right to buy) A-Award	Wyzga Michael S Director	Director	110 000 Value: $440.0K
Jan 01, 2026 Buy	Stock Option (right to buy) A-Award	De Craecker Francoise Director	Director	110 000 Value: $440.0K
Oct 29, 2025 Buy	Stock Option (right to buy) A-Award	Kirske David Chief Financial Officer	C-Suite Officer	1 552 769 Value: $2.20M
Oct 29, 2025 Buy	Stock Option (right to buy) A-Award	Volpone John President	CEO / President	2 329 154 Value: $3.31M
Oct 29, 2025 Buy	Stock Option (right to buy) A-Award	Craig Adam R Executive Chairman	CEO / President	2 329 154 Value: $3.31M
Oct 23, 2025 Buy	Common Stock P-Purchase	Craig Adam R Executive Chairman	CEO / President	86 206 Value: $250.0K
Aug 14, 2025 Buy	Stock Option (right to buy) A-Award	Volpone John President	CEO / President	529 201 Value: $1.66M
Aug 14, 2025 Buy	Common Stock A-Award	Volpone John President	CEO / President	289 881 Value: $910.2K
Aug 14, 2025 Buy	Stock Option (right to buy) A-Award	Craig Adam R Executive Chairman	CEO / President	529 201 Value: $1.66M
Aug 14, 2025 Buy	Common Stock A-Award	Craig Adam R Executive Chairman	CEO / President	289 881 Value: $910.2K
Aug 14, 2025 Buy	Stock Option (right to buy) A-Award	Kirske David Chief Financial Officer	C-Suite Officer	352 800 Value: $1.11M
Aug 14, 2025 Buy	Common Stock A-Award	Kirske David Chief Financial Officer	C-Suite Officer	193 254 Value: $606.8K
Aug 14, 2025 Buy	Common Stock A-Award	Kirske David Chief Financial Officer	C-Suite Officer	193 254 Value: $606.8K
Aug 14, 2025 Buy	Stock Option (right to buy) A-Award	Kirske David Chief Financial Officer	C-Suite Officer	352 800 Value: $1.11M
Aug 14, 2025 Buy	Common Stock A-Award	Craig Adam R Executive Chairman	CEO / President	289 881 Value: $910.2K
Aug 14, 2025 Buy	Stock Option (right to buy) A-Award	Craig Adam R Executive Chairman	CEO / President	529 201 Value: $1.66M
Aug 14, 2025 Buy	Common Stock A-Award	Volpone John President	CEO / President	289 881 Value: $910.2K
Aug 14, 2025 Buy	Stock Option (right to buy) A-Award	Volpone John President	CEO / President	529 201 Value: $1.66M
Aug 12, 2025 Buy	Stock Option (right to buy) A-Award	Volpone John President	CEO / President	1 609 873 Value: $2.29M
Aug 12, 2025 Buy	Common Stock J-Other	Craig Adam R Executive Chairman	CEO / President	0 Value: $0
Aug 12, 2025 Buy	Common Stock J-Other	Kirske David Officer	Officer	0 Value: $0
Aug 12, 2025 Buy	Stock Option (right to buy) A-Award	Craig Adam R Executive Chairman	CEO / President	1 609 873 Value: $2.29M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT X4 PHARMACEUTICALS INC.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and my...

Read Full Profile Here